Announcements Trials
Browse Landscape

Phase

Phase 1 2Phase 1/2 1

Status

Terminated 3Withdrawn 2Active not recruiting 2Unknown 1Completed 1

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Thoracic 2NET 1Endocrine 1

Conditions

Small Cell Lung Carcinoma 2Neuroendocrine Tumors 1

Interventions

Cyclophosphamide 389Carboplatin 343Gemcitabine 331pembrolizumab 328Cisplatin 327Paclitaxel 294Radiotherapy 291Docetaxel 285Bevacizumab 249Rituximab 233Capecitabine 221Nivolumab 218Dexamethasone 205Fluorouracil 189fludarabine 177Oxaliplatin 177Pemetrexed 153Doxorubicin 152Irinotecan 147Etoposide 144Leucovorin 143Cytarabine 133Bortezomib 129fludarabine phosphate 128Cetuximab 126Lenalidomide 125Filgrastim 119Erlotinib Hydrochloride 119Temozolomide 111Radiosurgery 110

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Terminated × Interventional × pelcitoclax × Clear all
NCT04893759 2025-04-17

A Study of Pelcitoclax (APG-1252) in Patients With Neuroendocrine Tumors

Ascentage Pharma Group Inc.

Phase 1 Terminated
2 enrolled
EndocrineNET

Neuroendocrine Tumors

NCT04210037 2022-07-12

Study of APG-1252 Plus Paclitaxel in Patients With Relapsed/Refractory Small Cell Lung Cancer

Ascentage Pharma Group Inc.

Phase 1/2 Terminated
28 enrolled
Thoracic

Small Cell Lung Carcinoma

NCT03387332 2021-08-27

APG-1252 in Patients With SCLC or Advanced Solid Tumors

Ascentage Pharma Group Inc.

Phase 1 Terminated
24 enrolled
Thoracic

Small Cell Lung Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡